Verapamil is a generic, decades-old calcium channel blocker that is being studied for beta-cell preservation in new-onset type 1 diabetes. In the TIDE trial and pediatric CLVer trial, once-daily verapamil preserved residual C-peptide and modestly improved glycemic measures. Use in T1D is off-label and typically managed by an endocrinologist.
What Verapamil Is
Verapamil is a non-dihydropyridine calcium channel blocker that has been used clinically since the 1970s for:
- Hypertension
- Stable angina and vasospastic angina
- Atrial fibrillation and supraventricular tachycardia (rate control)
- Hypertrophic cardiomyopathy
- Migraine prophylaxis (off-label)
- Cluster headache prophylaxis (off-label)
It is generic, inexpensive, and widely available in both immediate-release and extended-release oral forms.
Why It Was Studied for Type 1 Diabetes
Research from the 2010s showed that high glucose drives upregulation of TXNIP (thioredoxin-interacting protein) in pancreatic beta cells. TXNIP overexpression promotes oxidative stress and beta-cell apoptosis. Calcium channel blockers — verapamil in particular — reduce TXNIP expression in beta cells through inhibition of calcium-dependent transcription.
This suggested verapamil might slow the loss of beta cells in newly diagnosed type 1 diabetes, extending the “honeymoon period” of residual insulin secretion.
The TIDE Trial
The pivotal proof-of-concept trial (Ovalle et al., Nature Medicine 2018) enrolled 24 adults newly diagnosed with type 1 diabetes (within 3 months) and randomized them to oral verapamil titrated to 120 to 360 mg daily or matching placebo for 12 months.
| Outcome | Verapamil | Placebo |
|---|---|---|
| C-peptide AUC change at 12 months | Preserved (~30% better than placebo) | Declined |
| Insulin dose at 12 months | Lower | Higher |
| A1C at 12 months | Similar | Similar |
| Hypoglycemia events | Fewer trends | — |
The CLVer Trial (Pediatric)
Forlenza and colleagues (JAMA 2023) reported the CLVer trial in 113 children and adolescents (ages 7 to 17) newly diagnosed with T1D. Participants were randomized to verapamil (with weight-based dosing) or placebo, with simultaneous evaluation of automated insulin delivery.
- Verapamil group preserved 30 to 33 percent more C-peptide at 12 months versus placebo
- Effect persisted across age strata
- Generally well tolerated; constipation was the most common new side effect
- No serious cardiovascular events attributable to verapamil
CLVer is the strongest pediatric data so far supporting verapamil’s beta-cell preservation effect.
Mechanism in Beta Cells
- L-type calcium channels open in response to high glucose, causing calcium influx
- Calcium influx triggers TXNIP transcription via the carbohydrate response element binding protein (ChREBP) pathway
- Elevated TXNIP disrupts thioredoxin-mediated antioxidant defense and promotes apoptosis
- Verapamil’s L-type channel blockade reduces calcium-driven TXNIP, lowering apoptotic stress
- Beta cells survive longer, residual C-peptide preserved
Dosing in T1D Trials
- Adults: 120 mg daily, titrated up to 360 mg as tolerated
- Children (CLVer): weight-based, typically 60 to 120 mg/day, escalating to ~7 mg/kg/day maximum (varying by age and weight)
- Extended-release formulations used to allow once-daily dosing
- Starting within 1 to 3 months of T1D diagnosis maximizes effect on residual beta cells
Side Effects of Verapamil
Verapamil has a well-established safety profile from over 50 years of use:
- Constipation — common, often dose-limiting
- Headache
- Dizziness
- Peripheral edema (ankle swelling)
- Fatigue
- Bradycardia — slowed heart rate
- First-degree AV block — generally benign at lower doses
- Hypotension — uncommon at low to moderate doses
- Hepatic enzyme elevations — rare
- Significant drug interactions — especially with beta-blockers, digoxin, statins (atorvastatin, simvastatin), and CYP3A4 substrates
Cautions and Contraindications
- Existing significant bradycardia or conduction abnormality
- Severe heart failure with reduced ejection fraction
- Hypotension
- Concurrent beta-blocker use without specialist supervision
- Significant hepatic impairment
- Pregnancy (use weighed individually with prescriber)
Monitoring on Verapamil
- Baseline ECG to confirm normal conduction
- Blood pressure and heart rate at follow-up visits
- Periodic CMP for hepatic function
- Symptom monitoring for dizziness, constipation, edema
- Periodic C-peptide measurement to confirm preservation effect (in research contexts)
Verapamil Versus Teplizumab
| Feature | Verapamil | Teplizumab (Tzield) |
|---|---|---|
| Approval status for T1D | Off-label | FDA approved 2022 |
| Indication | New-onset T1D (Stage 3) | Stage 2 T1D |
| Mechanism | Reduces TXNIP-driven beta-cell apoptosis | Modulates T-cell autoimmunity |
| Administration | Daily oral tablet | 14-day IV infusion course |
| Cost | ~$5-20/month (generic) | ~$193,900 per course |
| Major side effects | Constipation, edema, bradycardia | Lymphopenia, rash, cytokine release |
The two work at different stages and mechanisms, and could in principle be complementary. Some research programs are exploring combination approaches.
Cost and Access
Verapamil is a generic medication — extended-release formulations typically cost $5 to $30 per month at most US pharmacies, often less with discount programs. Insurance coverage is universal for cardiovascular indications; off-label T1D use is typically still covered because the drug itself is inexpensive and broadly indicated.
Where It Fits in Type 1 Diabetes Care
Verapamil is one of several emerging strategies for beta-cell preservation and immune modulation in T1D. Related approaches include teplizumab, islet cell transplant, pancreas transplant, and stem cell therapy. For more on T1D care, see our overview of treatment and A1C levels.
What to Discuss with a Clinician
- Time since diagnosis — verapamil works best within months of T1D onset
- Residual C-peptide level (can be measured)
- Cardiovascular history, baseline ECG, and any conduction abnormalities
- Current medications, particularly beta-blockers, statins, and digoxin
- Realistic expectations — verapamil is preservation, not reversal
- Whether enrolling in an ongoing trial may offer additional structure
The Bottom Line
Verapamil is a generic, inexpensive calcium channel blocker now repurposed for off-label use in new-onset type 1 diabetes. The TIDE trial in adults and the CLVer trial in children both showed about 30 percent C-peptide preservation at 12 months versus placebo, with parallel modest glycemic benefits. The mechanism is reduction of TXNIP-driven beta-cell apoptosis. Side effects are those of any calcium channel blocker — constipation, edema, bradycardia, headache, dizziness. Verapamil is not a cure, but it may delay loss of residual beta-cell function. Talk to an endocrinologist about whether off-label use is appropriate within months of a T1D diagnosis.
